Moderate Evidence

Promising research with growing clinical support from multiple studies

Holistic Treatment for Alzheimer’s Disease

Alzheimer’s disease (AD) is a progressive neurodegenerative condition marked by memory loss, changes in thinking and behavior, and loss of independence. For families, the goals of care are often broader than slowing decline. Many prioritize day-to-day function, quality of life, emotional well‑being, safety, and reducing caregiver burden. A holistic approach means addressing the whole person within their social context. In Western medicine, “holistic” typically involves coordinated biomedical care plus lifestyle medicine, rehabilitation, and psychosocial supports. In Eastern traditions, it often adds pattern-based diagnosis, herbal formulas, acupuncture, and mind–body practices that aim to balance systems and support resilience. Comparing these perspectives helps people understand complementary options and the strength of evidence behind them. Western biomedical science views AD as driven by a combination of beta‑amyloid plaques, tau tangles, synaptic dysfunction, neuroinflammation, and vascular and metabolic factors, with genetics (e.g., APOE ε4) influencing risk. Clinicians diagnose using history, cognitive testing, functional assessment, and exclusion of other causes; imaging and biomarkers (MRI, CSF amyloid/tau, PET; and increasingly blood tests such as plasma phosphorylated‑tau) can improve diagnostic certainty, especially in early disease. Evidence‑based medications include cholinesterase inhibitors (donepezil, rivastigmine, galantamine) and memantine, which can modestly support cognition and daily function. Recently, anti‑amyloid antibodies (lecanemab and donanemab) showed in large randomized trials a small but statistically significant slowing of clinical decline in early AD with confirmed amyloid, though they require infusions, MRI monitoring, and shared decision‑making given risks such as amyloid‑related imaging abnormalities (ARIA). Non‑pharmacologic care is central: cognitive stimulation therapy (CST) and structured rehabilitation can support cognition,,

neurological Updated March 20, 2026

This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any supplement or medication regimen.

Western Medicine

Diagnosis

Clinical evaluation based on NIA–AA criteria integrating history, informant report, neuropsychological testing (e.g., MMSE, MoCA, ADAS‑Cog), and functional assessments (iADL/ADL). Imaging (MRI for atrophy/vascular disease) and biomarkers (CSF Aβ42/40, phosphorylated tau; amyloid or tau PET) increase diagnostic confidence in appropriate patients. Plasma p‑tau assays are emerging. Differential diagnosis includes depression, delirium, medication effects, thyroid/B12 deficiency, normal pressure hydrocephalus, and other dementias.

Treatments

  • Education, safety planning, advance care planning, and caregiver support programs
  • Cholinesterase inhibitors for symptomatic cognitive/functional support in mild to moderate stages
  • Memantine for moderate to severe stages, sometimes combined with a cholinesterase inhibitor
  • Anti‑amyloid monoclonal antibodies (for early AD with biomarker confirmation), with MRI monitoring and risk management
  • Cognitive stimulation therapy and individualized cognitive rehabilitation
  • Physical activity and balance training; occupational and speech therapy for function and communication
  • Lifestyle measures: heart‑healthy diet patterns (Mediterranean/MIND), sleep optimization and treatment of sleep apnea, hearing correction, vascular risk control (hypertension, diabetes, lipids), smoking/alcohol moderation
  • Management of neuropsychiatric symptoms (environmental modifications first; cautious, short‑term psychotropic use when needed)
  • Community resources: respite services, social work, caregiver training, and support groups

Medications

  • Donepezil
  • Rivastigmine
  • Galantamine
  • Memantine
  • Lecanemab
  • Donanemab

Limitations

Current medications provide modest symptomatic benefit; disease‑modifying antibodies slow decline by a small margin and are limited to early AD with confirmed amyloid. Risks (e.g., ARIA), monitoring burden, access, and cost are significant. Non‑pharmacologic benefits vary and require sustained delivery. Many trials underrepresent diverse populations, and no therapy halts or reverses the disease.

Evidence: Strong Evidence

Sources

  • A 2018 Cochrane review concluded cholinesterase inhibitors provide small improvements in cognition and activities of daily living in mild–moderate AD.
  • A 2019 Cochrane review reported memantine improves global and cognitive outcomes in moderate–severe AD.
  • The 2022 CLARITY‑AD randomized trial (NEJM) found lecanemab slowed decline on CDR‑SB over 18 months in early AD with amyloid confirmation.
  • The 2023 TRAILBLAZER‑ALZ 2 randomized trial (JAMA/NEJM) reported donanemab slowed decline in early symptomatic AD.
  • A Cochrane review of cognitive stimulation (updated 2018) found benefits for cognition and quality of life in mild–moderate dementia.
  • The 2020 Lancet Commission on dementia prevention highlighted risk reduction (hearing loss, hypertension, diabetes, inactivity, smoking, depression) and comprehensive care models.

Eastern & Traditional Medicine

Traditional Chinese Medicine (TCM) — herbs and acupuncture

TCM frames dementia as disturbances of the “orifices of the heart” with patterns such as Kidney essence deficiency, phlegm‑damp obstructing the mind, and blood/Qi stagnation. Treatment seeks to tonify essence, transform phlegm, move blood, and calm the spirit, aiming to support memory, sleep, mood, and daily function rather than a single disease target.

Techniques

  • Pattern‑based herbal formulas (e.g., bushen‑yi zhi–type tonics; formulas derived from Danggui‑Shaoyao‑San) individualized to presentation
  • Use of standardized extracts studied in dementia, such as Ginkgo biloba (EGb 761) and Huperzia serrata–derived huperzine A (AChE inhibition)
  • Acupuncture at commonly used points for cognition and mood (e.g., Baihui/GV20, Sishencong/EX‑HN1, Shenmen/HT7, Taixi/KI3, Zusanli/ST36), often 2–3 sessions weekly in studies
  • Moxibustion or scalp acupuncture in selected cases
  • Dietary guidance and gentle qigong for vitality
Licensed acupuncturist (L.Ac.) or TCM physician Herbalist trained in Chinese materia medica Integrative medicine physician with TCM training
Evidence: Emerging Research

Ayurveda

Ayurveda conceptualizes memory disorders under smriti‑bhramsha and related states, often linked to imbalances in Vata and depletion of ojas. Therapy emphasizes medhya rasayana (nootropic rejuvenatives), digestive/metabolic balance, and calming of the mind to support clarity, sleep, and behavior.

Techniques

  • Medhya herbs/formulas such as Bacopa monnieri (Brahmi), Withania somnifera (Ashwagandha), Centella asiatica (Gotu Kola), and Convolvulus pluricaulis (Shankhpushpi) per practitioner assessment
  • Lifestyle and dinacharya (daily routines) to stabilize sleep and stress responses
  • Abhyanga (oil massage) and shirodhara for calming in selected cases
  • Sattvic dietary guidance emphasizing easily digestible, nutrient‑dense foods
  • Breathwork (pranayama) and meditation for patients and caregivers
Ayurvedic practitioner (BAMS or equivalent training) Integrative/functional medicine clinician with Ayurvedic training
Evidence: Emerging Research

Kampo (Japanese traditional medicine)

Kampo uses fixed herbal formulas tailored to patient pattern (sho). In dementia care, it is often used to address behavioral and psychological symptoms (agitation, hallucinations, sleep disturbance) and frailty, aiming to improve comfort and caregiver burden.

Techniques

  • Formulas such as Yokukansan (Yi‑Gan San) for agitation, irritability, and sleep disturbance
  • Ninjin’yoeito to support appetite, energy, and frailty in some contexts
  • Close monitoring of pattern and tolerability by a Kampo‑trained physician
Physicians trained in Kampo (Japan) Integrative physicians familiar with Kampo formulas
Evidence: Moderate Evidence

Mind–body practices (qigong, tai chi, yoga, meditation)

Mind–body traditions aim to harmonize body, breath, and attention, potentially improving mood, sleep, balance, and stress physiology. In AD, evidence is more developed for mild cognitive impairment and caregiver outcomes, with smaller studies in dementia suggesting benefits for neuropsychiatric symptoms and quality of life.

Techniques

  • Gentle tai chi or qigong adapted for mobility
  • Yoga (chair‑based or restorative) and guided relaxation
  • Breath practices (e.g., pranayama) and structured meditation (e.g., Kirtan Kriya)
  • Mindfulness programs tailored for caregivers
Certified yoga therapist or instructor experienced with cognitive disorders Qigong/tai chi teacher for older adults Meditation teacher; clinical psychologists offering mindfulness‑based programs
Evidence: Emerging Research

Sources

  • A 2022 systematic review reported low‑ to moderate‑quality evidence that acupuncture added to donepezil improved MMSE versus donepezil alone, with high risk of bias and need for larger trials.
  • Cochrane reviews (2009–2012 updates) on Ginkgo biloba found mixed results; some trials with standardized extracts showed small benefits in cognition/ADL.
  • A Cochrane review (2013) on huperzine A suggested potential cognitive benefits in AD but highlighted methodological limitations of Chinese trials.
  • A 2021 systematic review found Bacopa monnieri improved some cognitive domains in adults and mild cognitive impairment; AD‑specific data are limited.
  • A small 2020 randomized trial in mild cognitive impairment reported improved memory with Withania somnifera versus control; AD evidence remains preliminary.
  • Classical Ayurvedic texts (Charaka Samhita) describe medhya rasayana for memory and intellect.
  • Randomized trials from Japan (2014–2017) found Yokukansan reduced Neuropsychiatric Inventory scores in dementia compared with usual care or placebo.
  • A 2019 systematic review concluded Yokukansan may benefit behavioral and psychological symptoms of dementia, with generally good tolerability.
  • A 2019 meta‑analysis reported tai chi improved global cognition in older adults with mild cognitive impairment; dementia‑specific data are limited but suggest benefits for mood and balance.
  • Small randomized studies found meditation practices improved sleep, stress, and memory measures in older adults with memory complaints and reduced caregiver distress.
  • Pilot trials in dementia reported improvements in neuropsychiatric symptoms and quality of life with adapted yoga or qigong, though sample sizes were small.

Integrative Perspective

Where available, standard Western therapies (diagnosis with biomarkers when appropriate, symptomatic drugs, and structured non‑pharmacologic care) form the backbone of treatment. Eastern modalities may complement these by targeting symptoms under‑served by medications—sleep disturbance, agitation, anxiety, apathy, constipation, and caregiver stress. Preliminary trials suggest acupuncture added to donepezil may enhance short‑term cognitive scores, and Kampo formula yokukansan may reduce agitation, potentially lowering reliance on sedatives. Mind–body programs can be incorporated into rehabilitation to support balance and reduce anxiety. Safety is crucial: discuss all herbs and supplements with clinicians. Ginkgo biloba may increase bleeding risk, particularly with anticoagulants or antiplatelet drugs. Huperzine A has cholinesterase‑inhibiting effects and could potentiate bradycardia or gastrointestinal side effects when combined with donepezil, rivastigmine, or galantamine. Ashwagandha and gotu kola have been associated (rarely) with liver or thyroid effects and may increase sedation when combined with CNS depressants. Quality control varies—prefer products tested by independent programs (e.g., USP/NSF) and practitioners with recognized credentials (e.g., L.Ac./NCCAOM for acupuncture, BAMS‑trained Ayurvedic clinicians). For anti‑amyloid infusions, ensure any added therapies do not increase fall, bleeding, or hypertension risk; coordinate timing around MRI monitoring. Evaluate studies and claims by checking for randomization, blinding, adequate sample size, pre‑registration, validated outcomes (ADAS‑Cog, CDR‑SB, NPI, QoL‑AD), and reporting of adverse events. Ethical, person‑centered care includes aligning interventions to patient/caregiver goals (comfort, function, mood, safety), cultural preferences, and stage of disease, with routine reassessment of benefit versus burden. Shared decision‑making meetings that include neurology, primary care, rehabilitation therapists, integrative practitioners, and family can help design a coherent plan and avoid polypharmacy or conflicting treatments. Consult your healthcare provider before making changes to your health regimen.

Sources

  1. NIA–AA research framework (2018) describing AT(N) biomarker approach; updates highlight biomarker‑informed diagnosis in early AD.
  2. Cochrane reviews (2018–2019) on cholinesterase inhibitors and memantine show modest symptomatic benefits.
  3. CLARITY‑AD (2022) lecanemab RCT demonstrated slowed clinical decline in early AD; TRAILBLAZER‑ALZ 2 (2023) reported similar findings for donanemab.
  4. Cochrane cognitive stimulation review (updated 2018) supports benefits for cognition and quality of life in dementia.
  5. Lancet Commission on dementia prevention, intervention, and care (2020) outlines risk reduction and comprehensive care.
  6. Systematic reviews (2019–2022) on acupuncture for AD suggest potential benefits with high heterogeneity and bias; higher‑quality trials needed.
  7. Cochrane and other systematic reviews report mixed evidence for Ginkgo biloba in dementia; huperzine A shows potential with low‑quality trials.
  8. Japanese trials and reviews suggest yokukansan improves behavioral symptoms of dementia with acceptable safety.
  9. Mind–body research indicates benefits for MCI and caregiver stress; dementia‑specific data are emerging.

Related Content

comparisons

Natural Remedies for Alzheimer’s Disease: East vs West

Natural Remedies for Alzheimer’s Disease. Alzheimer’s disease (AD) is a progressive neurodegenerative condition characterized by memory loss, cognitive decline, and functional impairment. Western biomedicine defines AD by pathological protein changes—amyloid-β plaques and tau tangles—leading to synaptic failure and brain atrophy. Diagnosis

comparisons

Alternatives for Alzheimer's Disease: East vs West

Alternatives for Alzheimer's Disease. Alzheimer’s disease (AD) is a progressive neurodegenerative condition marked by memory loss, impaired thinking, and changes in behavior. Biologically, it involves abnormal accumulation of amyloid-beta plaques and tau tangles, synaptic dysfunction, and neuroinflammation. While Western medicine has cl

comparisons

ADHD and Alternative Medicine — East vs West: East vs West

ADHD and Alternative Medicine — East vs West. Attention-deficit/hyperactivity disorder (ADHD) is a common neurodevelopmental condition marked by persistent patterns of inattention, hyperactivity, and/or impulsivity that interfere with functioning at school, work, or home. Comparing Western medical and Eastern traditional approaches can help fam

comparisons

Alternatives for Stroke Rehabilitation: East vs West

Alternatives for Stroke Rehabilitation. Stroke rehabilitation aims to restore movement, speech, cognition, sensation, and daily function after brain injury. Comparing Western and Eastern options matters because recovery is driven by neuroplasticity—the brain’s capacity to rewire with targeted, repetitive practice—and because people worldw

relationships

Alzheimer's Disease and Cardiovascular Disease

Alzheimer’s disease (AD) and cardiovascular disease (CVD) are tightly linked along a brain–heart axis. They share many modifiable risk factors—hypertension, diabetes, dyslipidemia, obesity, smoking, i

comparisons

Herbal Remedies for Attention Deficit Hyperactivity Disorder (ADHD): East vs West

Herbal Remedies for Attention Deficit Hyperactivity Disorder (ADHD). Attention-Deficit/Hyperactivity Disorder (ADHD) is a neurodevelopmental condition characterized by persistent patterns of inattention and/or hyperactivity-impulsivity that affect functioning at school, work, and in relationships. Comparing Western clinical care with Eastern traditions is useful beca

Health Disclaimer

This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any supplement or medication regimen.